EvolutionaryScale vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 55)
EvolutionaryScale logo

EvolutionaryScale

ChallengerHealthcare & Life Sciences

AI Protein Design & Biology

AI biology lab building protein design models (ESM3, 98B params). Founded 2023 by ex-Meta scientists. $142M seed. Acquired by Chan Zuckerberg Biohub Nov 2025.

AI VisibilityBeta
Overall Score
C55
Category Rank
#170 of 596
AI Consensus
72%
Trend
stable
Per Platform
ChatGPT
53
Perplexity
61
Gemini
57

About

EvolutionaryScale was an AI research lab founded in 2023 by former Meta AI protein team scientists, including CEO Alexander Rives. Based in New York City, the company developed frontier AI models for protein design and biological discovery. Its flagship model ESM3 is a 98-billion-parameter generative AI system trained on 2.78 billion protein sequences capable of reasoning over protein sequence, structure, and function simultaneously.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

55
Overall Score
81
#170
Category Rank
#17
72
AI Consensus
71
stable
Trend
stable
53
ChatGPT
80
61
Perplexity
75
57
Gemini
77
49
Claude
86
57
Grok
85

Key Details

Category
AI Protein Design & Biology
General
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only EvolutionaryScale
AI Protein Design & Biology

Integrations

Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.